Bridgebio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Accepted with Prescription Drug User Fee Act (PDUFA) action date of November 29, 2024; FDA not currently planning to hold an advisory committee meeting to discuss application
Marketing Authorization Application accepted by the European Medicines...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Cardiomyopathy | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Marketing | New Drug Applications | Pharmaceuticals